fda ends semaglutide shortage Novo's Wegovy and Ozempic removed from US list, compounders on notice semaglutide and fda shortage ends

While many people will respond to Wegovy and Ozempic for weight loss, up to about 15% of people will not respond to the drugs

isolated cagrilintide had a smaller effect

CVS Caremark selected Wegovy as its preferred GLP-1 for weight loss effective July 1, 2025, removing Zepbound from these formulary types: [2] Standard Control Formulary Most common employer formulary Advanced Control Formulary More restrictive formulary with lower premiums Value Formulary Cost-focused formulary used by smaller employers Background: The Zepbound Class Action Lawsuits In September 2025, two class action lawsuits were filed by Zepbound patients against CVS Caremark: [3][8] (Sept

(2S)-2-Azanyl-5-[[(2R)-3-[[(2R)-2-[[(4S)-4-azanyl-5-oxidanyl-5-oxidanylidene-pentanoyl]amino]-3-(2-hydroxy-2-oxoethylamino)-3-oxidanylidene-propyl]disulfanyl]-1-(2-hydroxy-2-oxoethylamino)-1-oxidanylidene-propan-2-yl]amino]-5-oxidanylidene-pentanoic acid

In just a few short years, these injectable peptide medications have completely reshaped the weight loss conversation

1 However, despite this surge in interest and the compelling narrative equating it with Ozempic, the central scientific question remains: Is there clinical and molecular evidence that justifies the comparison of Berberine to semaglutide